PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
CCENT/2006/59 - CB DIAGNOSTICS AB / SWEDEN DIA (SWEDEN) AB
Acquiring
Grupo Cinven
Description
an economic group that manages investment funds and other capital applications at an international level; it has shareholdings in a group of companies that are present in Portugal, especially in the following areas: (i) the development of distribution systems and technologies directed towards the tourism and travel sectors; (ii) the publication of business directories; (iii) academic publications, etc. CB DIAGNOSTIGS AB, which is a member of this group, is a company under Swedish law, set up for the purpose of acquiring SWEDEN DIA.
Acquired
Sweden Dia AB
Description
a company under Swedish law, controlled at present by Sweden Dia (Luxembourg) SA, which through its holdings, as the parent company of the Phadia Group, (i) produces and markets integrated in-vitro diagnostic devices for allergies and immunological diseases and (ii) produces and markets natural basic materials for allergology, in Portugal and at an international level.
Sector
  • Extractive and manufacturing Industries
Activity (NACE)
  • C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Applicable legislation
Art. 9(1)(a) (Law 18)
Notification thresholds
Market share
Type of merger
Conglomerate
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description
Notified on 30 November 2006, this merger consists of the acquisition by GRUPO CINVEN, via CB DIAGNOSTIGS AB, of sole control of the company SWEDEN DIA (SWEDEN) AB (henceforth "SWEDEN DIA"), by means of the ownership of its total share capital.
Timeline
2007-01-11
COMPETITION AUTHORITY approves the acquisition of sole control of the company SWEDEN DIA by GRUPO CINVEN, via CB DIAGNOSTIGS AB
Click here to see your activities